Detailed introduction to the main functions and effects of EIKANCE 0.01% Atropine Sulfate Eye Drops

0.01% atropine sulfate eye drops (trade name EIKANCE) is a low-concentration atropine eye drop, mainly used to control the progression of myopia in children, and has received widespread clinical attention in recent years. As the problem of myopia becomes increasingly serious, especially among children and adolescents, how to effectively slow down the progression of myopia has become an important issue in the field of ophthalmology. EIKANCEAs a low-dose atropine preparation, it has become the focus of attention of parents and doctors due to its safety and efficacy advantages. Its main functions, usage effects and related mechanisms will be introduced in detail below.

0.01%The main function of atropine sulfate eye drops is to slow down the progression of myopia in children. The essence of myopia is that the length of the anterior and posterior axis of the eyeball is too long, causing distant objects to be imaged in front of the retina, affecting vision. Although traditional high-concentration atropine eye drops are effective in controlling myopia, their clinical application is limited due to obvious side effects (such as light sensitivity, accommodation disorders, etc.). Atropine eye drops with a low concentration of 0.01% retain the effect of controlling myopia while greatly reducing the risk of side effects. Studies have shown that using atropine eye drops with a concentration of 0.01% can effectively slow down the growth rate of the axial length of the eye, thereby slowing down the progression of myopia.

The effectiveness of EIKANCE has been verified in multiple clinical trials. Long-term follow-up of children and adolescents showed that the rate of myopia progression in the group using 0.01%atropine sulfate eye drops was significantly lower than that in the control group. For example, in patients who use this drug, the average growth of the eye axis is slowed down by about 30%-50%, and the growth of myopia is also significantly controlled. At the same time, patients have better adaptability to light, fewer adverse reactions, and are suitable for long-term use. This efficacy makes EIKANCE one of the recommended drugs to control the progression of myopia in children.

0.01%The mechanism of action of atropine sulfate eye drops is related to its regulation of intraocular muscles and visual signal transmission. Atropine, as a non-selective anticholinergic drug, can inhibit the contraction of the ciliary muscle in the eye, reduce accommodative spasm, and thereby reduce the accommodative burden on the eye. In addition, atropine also affects various signaling pathways in the retina and choroid, blocking biochemical signals that promote axial growth and inhibiting excessive elongation of the eyeball. These combined effects make atropine an effective drug for controlling the progression of myopia.

When usingEIKANCE attention should be paid to a reasonable medication regimen and monitoring. It is generally recommended that children use 0.01% drops once a night under the guidance of an ophthalmologistAtropine sulfate eye drops. During treatment, visual acuity and axial length need to be reviewed regularly to evaluate the efficacy and detect possible side effects as early as possible. Although low concentrations of atropine are relatively safe, some patients may experience mild eye irritation, glare, or blurred vision. The safety of long-term use requires continued attention, and current studies support that long-term use is well tolerated.

In summary,0.01%Atropine Sulfate Eye DropsEIKANCE has become the preferred drug for the treatment of myopia in children due to its low dose, high safety and effective control of myopia progression. It not only significantly slows down the growth of the axial length of the eye and delays the progression of myopia, but also minimizes side effects and is suitable for long-term continuous use. For myopic children and parents, EIKANCE provides a scientific and effective intervention method to help protect children's visual health and reduce the risk of high myopia and related eye diseases in the future. However, any medication must be prescribed by a doctor, and a personalized treatment plan should be developed based on the individual's specific conditions to obtain the best therapeutic effect.

Reference materials:https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf